title: Reply: Dabigatran's 'real-world' data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials.
authors.forename: Torben Bjerregaard
authors.initials: TB
authors.lastname: Larsen
authors.forename: Lars Hvilsted
authors.initials: LH
authors.lastname: Rasmussen
authors.forename: Flemming
authors.initials: F
authors.lastname: Skjøth
authors.forename: Karen Margrete
authors.initials: KM
authors.lastname: Due
authors.forename: Torbjörn
authors.initials: T
authors.lastname: Callréus
authors.forename: Mary
authors.initials: M
authors.lastname: Rosenzweig
authors.forename: Gregory Y H
authors.initials: GY
authors.lastname: Lip
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011725:Pyridines / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D011725:Pyridines; D014859:Warfarin